SCHOTT Pharma AG & Co KgaA
XETRA:1SXP

Watchlist Manager
SCHOTT Pharma AG & Co KgaA Logo
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
Watchlist
Price: 26.62 EUR 1.53% Market Closed
Market Cap: 4B EUR
Have any thoughts about
SCHOTT Pharma AG & Co KgaA?
Write Note

SCHOTT Pharma AG & Co KgaA
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SCHOTT Pharma AG & Co KgaA
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
Revenue
€898.6m
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
E
Evotec SE
XETRA:EVT
Revenue
€777.1m
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
25%
Gerresheimer AG
XETRA:GXI
Revenue
€2B
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
5%
No Stocks Found

SCHOTT Pharma AG & Co KgaA
Glance View

Market Cap
4B EUR
Industry
Life Sciences Tools & Services

SCHOTT Pharma AG & Co KgaA is a DE-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Mainz, Hessen. The company went IPO on 2023-09-28. SCHOTT Pharma AG & Co. KGaA is a Germany-based Company, which designs advanced drug containment and drug delivery solutions for the pharmaceutical and biotech industries. The firm's product portfolio ranges from drug containment solutions to drug delivery systems manufactured in collaboration with industry partners. Its selection of pharmaceutical syringes, cartridges, vials, and ampoules is one of the widest and advanced on the market for injectable drugs.

1SXP Intrinsic Value
34.05 EUR
Undervaluation 22%
Intrinsic Value
Price

See Also

What is SCHOTT Pharma AG & Co KgaA's Revenue?
Revenue
898.6m EUR

Based on the financial report for Sep 30, 2023, SCHOTT Pharma AG & Co KgaA's Revenue amounts to 898.6m EUR.

What is SCHOTT Pharma AG & Co KgaA's Revenue growth rate?
Revenue CAGR 3Y
15%

Over the last year, the Revenue growth was 9%. The average annual Revenue growth rates for SCHOTT Pharma AG & Co KgaA have been 15% over the past three years .

Back to Top